USPTO granted Journey Medical Corporation Patent US12594252B2 covering methods of treating inflammatory skin conditions using reduced-dose minocycline compositions. The patent contains 39 claims and names six inventors. The invention relates to administering a pharmaceutical composition comprising a reduced dose of minocycline to achieve effective plasma or interstitial fluid concentrations for treating inflammatory skin conditions.

Pharmaceutical companies and drug manufacturers must consider this patent when developing or marketing minocycline-based treatments for inflammatory skin conditions. Competitors should conduct freedom-to-operate analyses to assess whether their products or methods fall within the scope of the granted claims. Generic manufacturers may explore design-around strategies or licensing opportunities.